MABVAX THERAPEUTICS HOLDINGS, INC. - FORM 10-Q/A - EX-99.1 - MABVAX THERAPEUTICS, INC. GRANTED AND PENDING PATENTS AND APPLICATIONS - August 12, 2015

Attached files

file filename
10-Q/A - 10-Q/A - MABVAX THERAPEUTICS HOLDINGS, INC.mbvx10qa_june302015.htm
EX-32 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex32.htm
EX-10.9 - EXCLUSIVE LICENSE TO UNIMOLECULAR ANTIBODIES, DATED OCTOBER 13, 2011, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-9.htm
EX-10.1 - NON-EMPLOYEE DIRECTOR COMPENSATION POLICY - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-1.htm
EX-10.5 - EMPLOYMENT AGREEMENT, DATED JULY 21, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND PAUL MAFFUID, PH.D. - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-5.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-2.htm
EX-10.4 - SECOND AMENDMENT TO THAT STANDARD INDUSTRIAL NET LEASE, DATED AUGUST 1, 2012, BY AND BETWEEN THE COMPANY AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-4.htm
EX-10.3 - FIRST AMENDMENT TO THAT STANDARD INDUSTRIAL NET LEASE, DATED MAY 6, 2010, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-3.htm
EX-10.8 - RESEARCH AND LICENSE AGREEMENT, DATED AS OF APRIL 7, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-8.htm
EX-10.6 - DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, DATED APRIL 15, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND GALLUS BIOPHARMACEUTICALS NJ, LLC - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-6.htm
EX-10.7 - EXCLUSIVE LICENSE AGREEMENT FOR "POLYVALENT CONJUGATE VACCINES FOR CANCER" (SK#14491), DATED AS OF JUNE 30, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-7.htm
EX-10.2 - STANDARD INDUSTRIAL NET LEASE, DATED AS OF MAY 23, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-2.htm
EX-10.10 - OPTION AGREEMENT, DATED AUGUST 29, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND JUNO THERAPEUTICS, INC. - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-10.htm
EX-10.11 - SBIR CONTRACT FROM NATIONAL CANCER INSTITUTE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-11.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-1.htm
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
 August 12, 2015
 

Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner
MabVax Therapeutics, Inc.
Owned Patents
1. US
14/468,827
26-Aug-2014
    
Pending
26-Aug-2034
NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
MabVax Therapeutics, Inc.
2. PCT
PCT/US2014/052631
26-Aug-2014
    
Pending
26-Aug-2034
NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
MabVax Therapeutics, Inc.
3. US
14/730,036
03-Jun-2015
    
Pending
03-Jun-2035
HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2
MabVax Therapeutics, Inc.
4. PCT
PCT/US2015/033954
03-Jun-2015
    
Pending
03-Jun-2035
HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2
MabVax Therapeutics, Inc.

 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer


--
 
 
 
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
August 12, 2015



 
 
Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner
MabVax Therapeutics, Inc.
Sloan-Kettering Institute for Cancer Research (SKI)
Licensed Applications and Patents
a) AU
67792/98
25-Mar-1998
750701
14-Nov-2002
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
b) CA
2,286,798
25-Mar-1998
228798
07-Jan-2014
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI

c) CH
98913180
25-Mar-1998
0996455
16-Dec-2009
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
d) DE
69841385.7
25-Mar-1998
    
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
e) EP
98913180
25-Mar-1998
0996455
16-Dec-2009
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI

 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer


--
 
 
 
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
August 12, 2015



Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner
f) FR
98913180
25-Mar-1998
0996455
16-Dec-2009
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI

g) GB
98913180
25-Mar-1998
0996455
16-Dec-2009
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
h) JP
10-543934
25-Mar-1998
4308918
15-May-2009
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
i) US
09/083,776
25-Mar-1998
6,660,714
9-Dec-2003
Granted
25-Mar-2018
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
j) US
10/205,021
25-Jul-2002
7,160,856
9-Jan-2007
Granted
7-Oct-2019
ALPHA-O-LINKED GLYCOCONJUGATES, METHODS OF PREPARATION AND USES THEREOF
SKI
k) US
10/898,410
23-Jul-2004
7,550,146
23-Jun-2009
Granted
1-Mar-2019
GLYCOPEPTIDE CONJUGATES AND USES THEREOF
SKI

 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer


--
 
 
 
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
August 12, 2015



Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner

l) US
08/196,154
21-Jan-1994
7,014,856
21-Mar-2006
Granted
30-Aug-2022 (Date of Expiration is 21-Mar-2023 but TD to
US 08/477,097 sets to this date)
GANGLIOSIDE-KLH CONJUGATE VACCINES PLUS QS-21
SKI
m) US
08/475,784
07-Jun-1995
6,967,022
22-Nov-2005
Granted
30-Aug-2022 (Date of Expiration is 22-Nov-2022 but TD to US 08/477,097 sets to this date)
GANGLIOSIDE-KLH CONJUGATE VACCINES PLUS QS-21
SKI
n) US
08/477,097
07-Jun-1995
6,936,253
30-Aug-2005
Granted
30-Aug-2022
GANGLIOSIDE-KLH CONJUGATE VACCINES PLUS QS-21
SKI
o) US
08/477,147
07-Jun-1995
7,001,601
21-Feb-2006
Granted
30-Aug-2022 (Date of Expiration is 21-Feb-2023 but TD to
US 08/477,097 sets to this date)
GANGLIOSIDE-KLH CONJUGATE VACCINES PLUS QS-21
SKI
p) US
08/481,809
12-Jul-2005
6,916,476
12-Jul-2005
Granted
12-Jul-2022
GANGLIOSIDE-KLH CONJUGATE VACCINES PLUS QS-21
SKI

q) EP
10184649.1
5-Jul-2002
    
Pending
5-Jul-2022
POLYVALENT CONJUGATE VACCINE FOR CANCER
SKI

 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer


--
 
 
 
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
August 12, 2015



Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner
r) US
10/752,945
6-Jan-2004
7,479,266
20-Jan-2009
Granted
23-Mar-2024
POLYVALENT CONJUGATE VACCINE FOR CANCER
SKI
s) US
12/262,729
31-Oct-2008
8,092,780
10-Jan-2012
Granted
16-Apr-2023
POLYVALENT CONJUGATE VACCINE FOR CANCER
SKI
t) US
13/314,521
8-Dec-2011
8,540,964
9/24/2013
Granted
5-Jul-2022
POLYVALENT CONJUGATE VACCINE FOR CANCER
SKI
u) US
13/951,795
26-Jul-2013
    
Allowed
5-Jul-2022
POLYVALENT CONJUGATE VACCINE FOR CANCER
SKI
v) AU
716699
26-Apr-1996
716699
1-Jun-2000
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
                 

 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer


--
 
 
 
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
August 12, 2015



Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner
w) CA
2,218,884
26-Apr-1996
2,218,884
8-Jul-2008
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
x) DE
96913895.7
26-Apr-1996
69635730
11-Jan-2006
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
y) EP
96913895.7
26-Apr-1996
0823913
11-Jan-2006
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
z) ES
96913895.7
26-Apr-1996
0823913
11-Jan-2006
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI

 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer


--
 
 
 
Exhibit 99.1:  MabVax Therapeutics, Inc. – Granted and Pending Patents and Applications
August 12, 2015




Country
Application
No.
Filing
Date
Patent
No.
Issued
Date
Status
Estimated Expiration Date*
Title
Owner
aa) FR
96913895.7
26-Apr-1996
0823913
11-Jan-2006
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
bb) GB
96913895.7
26-Apr-1996
0823913
11-Jan-2006
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
cc) IT
96913895.7
26-Apr-1996
0823913
11-Jan-2006
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI
dd) JP
1996-532802
26-Apr-1996
4166273
8-Aug-2008
Granted
26-Apr-2016
SYNTHESIS OF THE BREAST TUMOR-ASSOCIATED ANTIGEN DEFINED BY MONOCLONAL ANTIBODY MBr1 AND USES THEREOF
SKI


 
* Expiration dates may be increased or decreased by additions of time under Patent Term Adjustment (PTA), Patent Term Extension (PTE) and/or filing of a Terminal Disclaimer

Stock widget

Investing forum

MABVAX THERAPEUTICS HOLDINGS, INC. Reports